Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continuation study of ABT-874 in moderate to severe chronic plaque psoriasis
2007-005955-40Phase 3Terminated
- Sponsor
- Abbott Laboratories
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of briakinumab in psoriasis, sponsored by Abbott Laboratories. Primary endpoint: Physician's Global Assessment response. Started Aug 2008; status: terminated.
02
Drugs
briakinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2007-005955-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005955-40.